Circulating RNAs in Acute Congestive Heart Failure
United States200 participantsStarted 2016-08-17
Plain-language summary
The purpose of this American Heart Association-funded and NIH-funded study is to examine circulating RNAs in the acute CHF setting, how they change with decongestive therapy, and their function in vitro and in vivo.
The investigators are testing the hypothesis that ex-RNA levels change significantly during decongestion therapy and can be used as a marker of those individuals who respond to CHF therapy (in terms of cardiac structure or outcome). Additionally, the translational research design allows the investigators to assay the effects of these RNAs on tissue phenotypes in vitro.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age \>/= 18 years of age
✓. Assessment of LV function within the last year or planned during hospital admission
✓. Acute CHF diagnosis, requiring clinical signs and/or symptoms (including exertional or rest dyspnea, orthopnea or PND) AND
✓. N-terminal pro-BNP level \> 1000 pg/ml or BNP \> 400 pg/ml, OR
✓. Clinical evidence of congestion:
✓. Clinical response to IV diuretic therapy (as judged by a physician)
Exclusion criteria
✕. Hematocrit at time of consent \< 30%
✕. End-stage non-cardiovascular diseases
✕. Known HIV/AIDS
✕. Cirrhosis
✕. Hemodialysis-dependent renal failure
What they're measuring
1
Plasma RNAs levels (rpm by RNAseq) in patients with acute CHF
Timeframe: admission vs. decongestion (up to 2 weeks)